Parp Inhibitors
Parp Enzyme

Parp Enzyme

With the boom of technology and scientific findings, researchers are studying more and more of the body to discover its functions and how to cure different diseases. Parp inhibitors are also known as Poly (ADP-ribose) polymerase, are a vital enzyme to our survival and even our DNA. This enzyme helps to regulate the body when there has been damage to our DNA, and can help normal cells function properly. Did you know that our DNA undergoes damage, change, and even evolution over time? There are many different variables that cause this affect in our body. As you know, whenever there is a change in any body part or function, there is an equal and opposite reaction in another part of our body.

Scientists have proposed the idea of using Parp inhibitors for targeting cancer cells. This new drug is thought to disrupt the chemotherapy resistance in the cells containing cancer. They may generally be used on those who suffer from ovarian, breast, and prostate cancer, due to their rate of metastasis. Parp inhibitor drugs are being tested around the globe, while clinical trials are being conducted and recorded.

This enzyme can target and help to stop the growth of cancer cells BRCA1, BRCA2 and inhibitor azd2281, which are proteins pertaining to our DNA. It is effective because this drug has anti-tumor properties that are thought to repair damage to normal cells and DNA. Also, researchers are also watching for any alternate reactions or side effects, where they have documented no damage to normal cells within the body. This process is still being conducted by scientists, and if it is proven successful, this could be a major life saver of people today. Scientists have documented in clinical trials the effect of these parp inhibitors specifically on cancerous cells. The effect was amazing, as it created cell-cycle arrest to occur in these diseased cells. Only minor physical affects were present after the study was completed, which involved nausea, constipation, fatigue, and neutropenia, all of which were documented to be minor in nature. The variable used on groups of different individuals with different stages of ovarian, prostate and breast cancer was the amount and frequency of chemotherapy used. Out of thirty four patients, they showed a thirty one percent response to the new drug therapy. All patients showed similar results after the test was concluded.

Oncologists recognized a sixty percent survival rate of those with triple negative breast cancer which is very hard to treat. This may be due to the agent Iniparib, which stops the growth and spread of cancer cells. This method of treating cancer may become very appealing and desired by many people because it is proving to be less toxic to the body as compared to chemotherapy. This adds a new spin to the treatment of cancer. However, despite the very exciting and new information available on this drug, the future of parp inhibitors is unclear at the moment due to the process of compiling scientific data and results for the treatment of cancer.

 

Comment About Parp Inhibitors